Dual Immunotherapy Achieves 51% Complete Response in Rare Aggressive Lymphoma

Extranodal NK/T-cell lymphoma (ENKTL) is a rare but highly aggressive blood cancer with a particularly poor prognosis once patients relapse or become refractory to initial treatment. Existing salvage therapies offer limited and short-lived benefit, making novel approaches urgently needed.

This phase 2 clinical trial, registered as NCT04763616, enrolled 37 patients with relapsed or refractory ENKTL and treated them with a combination of cemiplimab, a PD-1 checkpoint inhibitor, and isatuximab, an anti-CD38 antibody. The scientific rationale was that blocking CD38 could amplify the antitumor immune response triggered by PD-1 inhibition, addressing a key resistance mechanism. Treatment was administered intravenously every 4 weeks for 6 cycles, with responders continuing on a maintenance schedule for up to 24 months.

Results were striking. The complete response rate reached 51%, exceeding the pre-specified primary endpoint of 40%. The overall objective response rate was 65%. After a median follow-up of 30.2 months, median overall survival had not yet been reached — a meaningful benchmark in a disease where survival is typically measured in months. Median progression-free survival was 9.5 months, and the median duration of response among responders was 29.4 months, suggesting durability uncommon in this setting.

Biomarker analyses identified structural variations disrupting the PD-L1 3'-UTR region and high PD-L1 expression as predictors of response, offering a potential path toward patient selection strategies. The safety profile was manageable, with grade 3 or higher adverse events in 32% of patients and no treatment-related deaths.

While these findings are highly promising, the small sample size and single-arm design limit definitive conclusions. Randomized controlled trials will be needed to confirm superiority over current standards of care and validate the identified biomarkers clinically.